A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Irinotecan; Oxaliplatin
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 05 Jun 2013 Biomarkers information updated
- 13 Oct 2007 Status changed from in progress to completed.
- 30 Oct 2006 Status change